undamentalytics Newsletter
Sign in

Corcept Therapeutics Inc balance sheet

At the end of fiscal 2025, Corcept Therapeutics Inc had total assets of $837m, total liabilities of $189m and shareholders' equity of $648m. It held $120m in cash against $0 of debt: net cash of $120m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents2452314231767866136128120111
Receivables—1015182026283141546077
Inventory—25555568121313
Total current assets—66124237307479266499459472485440
Total assets—69221312412572424583622841837889
Accounts payable—29881171217154015
Deferred revenue (current)—0——————————
Total current liabilities—27303639474872105141166154
Short-term debt—150—————————
Long-term debt—00—————————
Total debt0150000000000
Total liabilities——303641484882115161189183
Shareholders' equity2241191276371523376502507680648706
Net debt (negative = net cash)−24−37−31−42−31−76−78−66−136−128−120−111
Shares outstanding—113m115m115m115m117m106m108m103m105m106m—

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CORT vs SUPNAXSM vs CORTCORT vs PCRX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Corcept Therapeutics Inc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Corcept Therapeutics Inc.